Open AccessAutologous Whole Blood Injection For COVID-19 Can Reduce Cytokine Storm and Severity of Illness
Author(s) -
M Christopher,
C. Jerriton Brewin,
Ramesh Babu,
M. Mohamed Arafath,
J. Auspas,
S R Tiruvalavan
Publication year - 2021
Publication title -
international journal of medical research and review
Language(s) - English
Resource type - Journals
eISSN - 2321-127X
pISSN - 2320-8686
DOI - 10.17511/ijmrr.2021.i03.02
Subject(s) - medicine , autologous blood , cytokine storm , covid-19 , adjuvant , randomized controlled trial , whole blood , cytokine , surgery , immune system , disease , immunology , infectious disease (medical specialty)
Autologous whole blood injection is used for various indications. It has an immunomodulatory actionon the immune system. A randomized controlled two-arm study was conducted to determine IL-6levels, CT changes and mortality among adult COVID-19 patients. The trial included 30 patientsdivided into two groups. The interventional group received 2 doses of 2.5 ml of autologous wholeblood injection spaced 2 days apart. There was a statistically significant reduction in IL-6 levels onday 6 in the group receiving treatment. CT score improved in patients who received treatment. Nocases of mortality were reported in the treatment group. Autologous whole blood injection can beused as a simple, low-cost adjuvant in the treatment of adult COVID-19 patients, regardless ofdisease severity.